74 results match your criteria: ""Saint Andrew's" General Hospital of Patras[Affiliation]"
J Peripher Nerv Syst
March 2015
Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy.
We aimed at validating the role of genetic variants identified by a recent genome-wide association study (GWAS) as determinants of chronic oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Eight polymorphisms (rs10486003, rs2338, rs843748, rs797519, rs4936453, rs12023000, rs17140129, and rs6924717) were genotyped in a total of 150 colorectal cancer patients of Caucasian origin receiving oxaliplatin-based chemotherapy. The severity grade of chronic OXAIPN was assessed by NCI-CTC criteria and the clinical version of the Total Neuropathy Score(©) (TNSc(©) ).
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
November 2014
Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Clinical specimens from 565 patients hospitalized in 2 intensive care units (ICUs A and B) during a 28-month period were cultured on appropriate media for isolation of Candida. Forty-nine (9%) patients had at least a Candida spp.-positive sample.
View Article and Find Full Text PDFArch Toxicol
September 2014
Department of Neurology, "Saint Andrew's" State General Hospital of Patras, 26335, Patras, Greece,
This review paper provides a critical exploration of updates concerning the spectrum of characteristics and treatment options of bortezomib-induced peripheral neuropathy (BIPN). Emphasis is given on pathogenesis issues. Although the mechanism underlying BIPN still remains elusive, it is increasingly acknowledged that the inhibition of proteasome activity in dorsal root ganglia and peripheral nerves, the mitochondrial-mediated disruption of Ca⁺⁺ intracellular homeostasis and the disregulation in nuclear factor κB and brain-derived neurotrophic factor play a significant pathogenic role.
View Article and Find Full Text PDFCancer Manag Res
June 2014
Department of Medicine-Division of Oncology, University of Patras Medical School, Rion-Patras, Greece.
Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of chemotherapy-induced peripheral neuropathy (CIPN) characteristics so as to highlight areas of future research to pursue on the topic. Current knowledge shows that the pathogenesis of CIPN still remains elusive, mostly because there are several sites of involvement in the peripheral nervous system.
View Article and Find Full Text PDFEpileptic Disord
March 2014
Department of Neurology, Saint Andrew's General Hospital of Patras, Patras, Greece.
Cobalamin deficiency is included in the spectrum of very uncommon underlying causes of status epilepticus (SE) and the literature contains very few such cases. We herein report a case of unusual presentation of cobalamin (vitamin B12) deficiency with de novo SE with the intention to bolster the argument that a de novo manifestation of SE due to cobalamin deficiency might not be that uncommon. We also support the importance of prompt identification and treatment of the underlying causes of SE, particularly those which are uncommon.
View Article and Find Full Text PDFCancer
October 2013
Department of Neurology, "Saint Andrew's" General Hospital of Patras, Patras, Greece; Laboratory of Molecular Oncology, Division of Oncology, Department of Medicine, University Hospital of Patras, Rion-Patras, Greece.
Background: The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage-gated sodium channels (SCNAs) genes that might confer susceptibility to an increased incidence and severity of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients treated with either leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or oxaliplatin plus capecitabine (XELOX) for colorectal cancer (CRC).
Methods: A total of 200 patients with CRC were genotyped with real-time polymerase chain reaction using locked nucleic acid hydrolysis probes or allele-specific primers. All patients had received oxaliplatin-based chemotherapy, either in the adjuvant or metastatic setting.
Eur J Neurol
May 2013
Department of Neurology, Saint Andrew's State General Hospital of Patras, Patras, Greece.
Background And Purpose: The aim of this post hoc analysis of data extracted from a prospective, multicenter study is to test in a large homogenous population of chemotherapy-naïve patients with colorectal cancer (CRC) treated with oxaliplatin (OXA)-based chemotherapy whether advanced age increases the risk of developing OXA-induced peripheral neuropathy (OXAIPN).
Methods: One-hundred and forty-five patients with CRC, without other significant co-morbidities predisposing to peripheral neuropathy, were divided according to their age into two groups: patients aged between 50 and 68 years (group I, n = 75); and patients aged ≥ 69 years (group II, n = 70). Patients were prospectively monitored at baseline and followed-up during chemotherapy using the motor and neurosensory National Cancer Institute Common Toxicity criteria, the clinical version of the Total Neuropathy Score and neurophysiology.
Ann Oncol
December 2012
Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain. Electronic address:
Background: To report our prospective experience on the incidence and pattern of oxaliplatin (OXA)-induced peripheral neuropathy (OXA-IPN) in patients with colorectal cancer (CRC) treated with either FOLFOX-4 or XELoda + OXaliplatin (XELOX).
Patients And Methods: One hundred and fifty patients scheduled to be treated with either FOLFOX or XELOX for CRC were prospectively monitored at baseline and followed-up during chemotherapy. The incidence and severity of symptoms secondary to OXA-IPN were recorded using three different types of assessment, i.
J Emerg Med
January 2013
Department of Neurology, Saint Andrew's General Hospital of Patras, Patras, Greece.
Background: Osteoblastomas are rare benign bone tumors that are mostly found in the posterior spinal elements; about 20% are located in the cervical spine.
Objective: The case of a destructive cervical osteoblastoma at C5 is reported in a 19-year-old man who initially presented with spastic quadriparesis.
Case Report: A 19-year-old man was self-referred, reporting symptoms in keeping with a progressive spastic quadriparesis, which had suddenly developed 6 days earlier.
Acta Neuropsychiatr
October 2011
Department of Neurology, "Saint Andrew's" General Hospital of Patras, Patras, Greece.
Unlabelled: Karanasios P, Loukopoulou P, Zampakis P, Tiligadas T, Makridou A, Doukas V, Argyriou AA. Foreign accent syndrome caused by a left temporal-parietal ischaemic stroke.
Aim: We present the first reported case of a Greek patient with foreign accent syndrome (FAS) secondary to a left temporal-parietal ischemic stroke.
Crit Rev Oncol Hematol
April 2012
Department of Neurology, Saint Andrew's General Hospital of Patras, Greece.
The peripheral nervous system can be vulnerable to the toxic action of several drugs since it is not protected as effectively as the central nervous system from noxious exogenous agents. Drug-induced neurotoxicity can affect the nerve fibers or the neuronal bodies (generally the dorsal root ganglia of the primary sensory neurons). Among the neurotoxic drugs antineoplastic agents represent a major clinical problem, given their widespread use and the potential severity of their toxicity.
View Article and Find Full Text PDFJ Pain Symptom Manage
December 2011
Department of Neurology, Saint Andrew's State General Hospital of Patras, Patras, Greece.
Context: Epothilones, belonging to the family of microtubule stabilizing agents, have shown prolonged remissions and improved survival in various types of refractory, treatment-resistant cancer. Ixabepilone (BMS-247550) is the main representative of these compounds. Peripheral neuropathy is a significant toxicity of epothilones, eventually resulting in dose modification and changes in the treatment plan.
View Article and Find Full Text PDFQual Life Res
December 2011
Department of Neurology, Saint Andrew's State General Hospital of Patras, 26335 Patras, Greece.
Purpose: Our aim was to assess the perceived emotional burden and quality of life (QOL) in a sample of Greek primary caregivers of patients with multiple sclerosis (MS).
Methods: Twenty-two male and 13 female primary caregivers (mean age 47.3 ± 12.
J Pain Symptom Manage
October 2011
Department of Neurology, Saint Andrew's State General Hospital of Patras, Patras, Greece.
Context: Several studies have investigated the prevalence of sleep disorders in patients suffering from multiple sclerosis (MS) and have shown that up to 54% of patients may have significantly more sleep problems than the general population. To our knowledge, however, no data are available about the quality of sleep of the primary caregivers of patients with MS.
Objectives: The objectives of the current cross-sectional study were to assess the quality of sleep in Greek primary caregivers of patients with MS and to investigate its relationship with the degree of caregivers' emotional distress.
J Neurol
June 2011
Department of Neurology, Saint Andrew's State General Hospital of Patras, 26335, Patras, Greece.
The first objective of the current observational study was to assess the degree of religiosity in Greek Christian Orthodox primary caregivers of patients with multiple sclerosis (MS). The second objective was to evaluate the interrelations between religiosity and quality of life (QOL) and to identify the determinants of QOL, an endpoint of considerable importance in clinical research and practice. Twenty-two male and 13 female primary caregivers (mean age 47.
View Article and Find Full Text PDFJ BUON
December 2010
Department of Neurology, Saint Andrew's General Hospital of Patras, and Department of Pathology, University of Patras Medical School, Rion-Patras, Greece.
Peripheral neuropathy ranks among the most common non-haematological adverse effects of a number of effective chemotherapeutic agents, including platinum compounds, taxanes and vinca alkaloids. Newer agents, such as bortezomib, thalidomide and lenalidomide, frequently exert similar neurotoxic effects on peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) may result from a variety of mechanisms and may be related to causal factors, such as single dose per course, cumulative dose and risk factors including treatment schedule, prior or concomitant administration of other neurotoxic agents, age and pre-existing peripheral neuropathy of other causes.
View Article and Find Full Text PDFJ Pain Symptom Manage
January 2011
Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Rion-Patras, Greece.
Context: In recent years, there is growing evidence in the medical literature to support an association between administration of commonly used chemotherapeutic agents and an increased risk for cognitive impairment.
Objectives: We herein critically summarize data relating to the pathophysiological mechanisms by which chemotherapy may induce cognitive impairment in patients surviving from solid tumors. The clinical and epidemiological characteristics and the proposed management strategies to counter chemotherapy-induced cognitive impairment (CICI) also are presented.
Neurodegener Dis
July 2011
Department of Neurology, Saint Andrew's State General Hospital of Patras, Patras, Greece.
To our knowledge, we describe for the first time the case of a male patient with sporadic young-onset amyotrophic lateral sclerosis, most likely attributed to chronic regular cocaine use and abuse. Our case supports the view that cocaine use and abuse may trigger a process of motor neuron degeneration by mechanisms implicating alterations in the neurobiology of the excitatory neurotransmitter glutamate and its receptors.
View Article and Find Full Text PDFJ Clin Neurophysiol
April 2010
EMG Laboratory, Department of Neurology, Saint Andrew's State General Hospital of Patras, Patras, Greece.
We sought to identify significant ulnar nerve conduction abnormalities and also to detect ulnar F-wave variable changes in patients with secondary progressive multiple sclerosis (MS). Conventional conduction study was performed unilaterally to ulnar nerves of eight men and 12 women with secondary progressive MS (mean age, 47.5 +/- 6.
View Article and Find Full Text PDFMol Med
September 2009
Department of Neurology, Saint Andrew's State General Hospital of Patras, Greece.
Conventional treatment options, including corticosteroids, intravenous immunoglobulin, or plasma exchange, often fail to treat dysimmune neuropathies, such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and monoclonal gammopathy with its subtypes. Therefore, a significant percentage of patients require adjunctive immunosuppressive therapies. Considering that even immunosuppressive agents often are ineffective and/or associated with significant toxicities, the need for the development of safe and effective new treatment options is rising.
View Article and Find Full Text PDFNeurol Sci
October 2009
Department of Neurology, Saint Andrew's General Hospital of Patras, 26335, Patras, Greece.
Myasthenia gravis (MG) can rarely be manifested with ocular motility disturbances, simulating internuclear ophthalmoplegia. Pseudo-internuclear ophthalmoplegia (PINO) may occur during the course of MG, however, the initial presentation of MG with PINO in rather unlikely. We herein describe the case of a male patient who developed PINO, as an initial manifestation of MG.
View Article and Find Full Text PDFReprod Sci
October 2008
Department of Neurology, Saint Andrew's General Hospital of Patras, Greece.
During the previous decades, women with Multiple Sclerosis (MS) were discouraged from having children, as pregnancy was deemed dangerous for pregnancy outcome and a contributing factor for exacerbation of MS. Current knowledge shows that women with MS are no more likely to have pregnancy or delivery complications compared to healthy women. Immunomodulatory therapies should be avoided during pregnancy and while breastfeeding.
View Article and Find Full Text PDFBlood
September 2008
Department of Neurology, Saint Andrew's General Hospital of Patras, Greece.
Bortezomib has demonstrated significant activity in clinical trials, mainly against recurrent or newly diagnosed multiple myeloma (MM). Peripheral neuropathy is a significant toxicity of bortezomib, requiring dose modification and potential changes in the treatment plan when it occurs. The mechanism underlying bortezomib-induced peripheral neuropathy (BIPN) is unknown.
View Article and Find Full Text PDFMuscle Nerve
June 2008
Department of Neurology, Saint Andrew's General Hospital of Patras, Patras, Greece.
Intramedullary tumors of the spinal cord are rare neoplasms that can be associated with severe neurological and functional handicaps. To our knowledge, we describe for the first time the case of a male patient who developed bilateral drop foot as an initial manifestation of a primary tumor in the conus medullaris of the spinal cord, probably an astrocytoma.
View Article and Find Full Text PDF